Therapeutic effect of osthole on hyperlipidemic fatty liver in rats

Acta Pharmacologica Sinica

Volumn 28, Issue 3, 2007, Pages 398-403

  Zhang, Yan ^a   Xie, Mei Lin ^a   Zhu, Lu Jia ^a   Gu, Zhen Lun ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Hyperlipidemic fatty liver; Osthole; Pharmacology

Indexed keywords

CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OSTHOLE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVITY; FATTY LIVER; FEEDING; HYPERLIPIDEMIA; LIPID STORAGE; LIVER WEIGHT; MALE; NONHUMAN; OXIDATION; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CNIDIUM; COUMARINS; FATTY LIVER; HYPERLIPIDEMIAS; LIPASE; LIPIDS; LIVER; MALE; MICE; PROCETOFEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33847206106     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00533.x     Document Type: Article

References (25)

1. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-5.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
3. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
4. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1222?4.
5. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Can Med Assoc J 2005; 172: 899-905.
6. Yang XH, Li SM, Ma FG. Study on the sterilization of Cnidium monnieri solution. Guangzhou Med J 1997; 28: 14-5. Chinese.
7. Basnet P, Yasuda I, Kumagai N, Tohda C, Nojima H, Kuraishi Y, et al. Inhibition of itch-scratch response by fruits of Cnidium monnieri in mice. Biol Pharm Bull 2001; 24: 1012?5.
8. Liu JX, Zhang WP, Zhou L, Wang XR, Lian QS. Anti-inflammatory effect and mechanism of osthole in rats. J Chin Med Mater 2005; 28: 1002?6. Chinese.
9. Wang SH, An F, Zhang DS, Zhang L. Experiment study on antioxidation effect of osthole. Chin Tradit Patent Med 2005; 27: 488?9. Chinese.
10. Zhou J, Cheng WX, Xu YH. Experimental study on anti-tumour effect of osthole extracted from the fruits of Cnidium monnieri (L.) Cusson. Zhejiang J Integr Tradit West Med 2002; 12: 76-8. Chinese.
11. Okamoto T, Kawasaki T, Hino O. Osthole prevents anti-Fas antibody-induced hepatitis in mice by affecting the caspase-3-mediated apoptotic pathway. Biochem Pharmacol 2003; 65: 677-81.
12. Yan M, Lu RJ, Jia XQ, Meng FL, Zhao XC. An experimental study on treating hyperlipidemic fatty liver with simvastain. Chin J Dig 2002; 22: 223-5. Chinese.
13. Ni HC, Li J, Jin Y, Zang HM, Peng L. The experimental animal model of hyperlipidemia and hyperlipidemic fatty live in rats. Chin Pharmacol Bull 2004; 20: 703-8. Chinese.
14. Tang Y, Tang ZZ, Yang L, Wang XK, Qiu W. Experimental study on treatment of fatty liver with hyperlipemia by xiao-zhi potion in rat model. Pharm J Chin PLA 2003; 6: 429-31. Chinese.
15. Cai BX, Xie ML, Gu ZL. The interactions of effective site clusters from Danshen and Shanzha on blood lipid of hyperlipidemic mice by orthogonal experimental design. Chin Tradit Herb Drugs 2004; 35: 192-4. Chinese.
16. Huang ZS, Wang ZW, Liu MP, Wu QG, Zhou L. Pharmacodynamic study on anti-fatty liver of hujin pills. Chin Tradit Patent Med 1998; 20: 27-8. Chinese.
17. Zhong L, Fan JG, Wang GL, Wu WQ, Jiang JM, Shi Q, et al. The establishment of nonalcoholic steatohepatitis (NASH) animal model. J Chin Prac Med 2000; 2: 3-6. Chinese.
18. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072-81.
19. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
20. Bos G, Snijder MB, Nijpels G, Dekker JM, Stehouwer CD, Bouter LM, et al. Opposite contributions of trunk and leg fat mass with plasma lipase activities: the hoorn study. Obes Res 2005; 13: 1817-23.
21. Merkel M, Heeren J, Dudeck W, Rinninger F, Radner H, Breslow JL, et al. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem 2002; 277: 7405-11.
22. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005; 28: 2181-6.
23. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscl Throm Vas 2004; 24: 1750-4.
24. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
25. Zeng MD. Pathogenesis and two "hits" hypothesis of fatty liver. Chin J Dig 2002; 22: 167-8. Chinese.